Specific N-glycans of Hepatocellular Carcinoma Cell Surface and the Abnormal Increase of Core-α-1, 6-fucosylated Triantennary Glycan via N-acetylglucosaminyltransferases-IVa Regulation

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Nie, Huan ^a   Liu, Xia ^a,d   Zhang, Yubao ^c   Li, Tingting ^a   Zhan, Chao ^c   Huo, Wenjuan ^a   He, Anshun ^a   Yao, Yuanfei ^a   Jin, Yu ^c   Qu, Youpeng ^a   Sun, Xue Long ^b   Li, Yu ^a  

^a HARBIN INSTITUTE OF TECHNOLOGY   (China)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d MUDANJIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

N ACETYLGLUCOSAMINYLTRANSFERASE; POLYSACCHARIDE;

ADULT; CARCINOGENESIS; CASE CONTROL STUDY; CELL MOTION; FEMALE; GLYCOSYLATION; HEP-G2 CELL LINE; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GLYCOSYLATION; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; N-ACETYLGLUCOSAMINYLTRANSFERASES; POLYSACCHARIDES;

EID: 84946606398     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16007     Document Type: Article

References (49)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
2. Altekruse, S. F., McGlynn, K. A. & Reichman, M. E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27, 1485-91 (2009).
3. Hart, G. W. & Copeland, R. J. Glycomics hits the big time. Cell 143, 672-6 (2010).
4. Hauselmann, I. & Borsig, L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol 4, 28 (2014).
5. Fuster, M. M. & Esko, J. D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5, 526-42 (2005).
6. Christiansen, M. N. et al. Cell surface protein glycosylation in cancer. Proteomics 14, 525-46 (2014).
7. Dall'Olio, F. et al. Expression of beta-galactoside alpha2,6 sialyltransferase and of alpha2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis. Glycobiology 14, 39-49 (2004).
8. Mehta, A. et al. Increased levels of tetra-antennary N-linked glycan but not core fucosylation are associated with hepatocellular carcinoma tissue. Cancer Epidemiol Biomarkers Prev 21, 925-33 (2012).
9. Callewaert, N. et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10, 429-34 (2004).
10. Laroy, W., Contreras, R. & Callewaert, N. Glycome mapping on DNA sequencing equipment. Nat Protoc 1, 397-405 (2006).
11. Liu, X. et al. Cell surface-specific N-glycan profiling in breast cancer. PLoS One 8, e72704 (2013).
12. Goldman, R. et al. Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res 15, 1808-13 (2009).
13. Vanhooren, V. et al. N-glycomic changes in serum proteins during human aging. Rejuvenation Res 10, 521-531a (2007).
14. Vanhooren, V., Laroy, W., Libert, C. & Chen, C. N-glycan profiling in the study of human aging. Biogerontology 9, 351-6 (2008).
15. Blomme, B. et al. Impact of elevation of total bilirubin level and etiology of the liver disease on serum N-glycosylation patterns in mice and humans. Am J Physiol Gastrointest Liver Physiol 298, G615-24 (2010).
16. Chen, C. C. et al. Altered serum glycomics in Alzheimer disease: a potential blood biomarker? Rejuvenation Res 13, 439-44 (2010).
17. Chen, C. et al. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. J Proteome Res 8, 463-70 (2009).
18. Vanderschaeghe, D. et al. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 8, 986-94 (2009).
19. Gui, H. L. et al. Altered serum N-glycomics in chronic hepatitis B patients. Liver Int 30, 259-67 (2010).
20. Liu X. E. et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 5, 1426-35 (2007)
21. Fang, M. et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer 127, 148-59 (2010).
22. Zhao, Y. P. et al. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer 118, 639-50 (2012).
23. Debruyne, E. N. et al. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem 56, 823-31 (2010).
24. Zhao, Y. P. et al. Decreased core-fucosylation contributes to malignancy in gastric cancer. PLoS One 9, e94536 (2014).
25. Liu, L. et al. The identification and characterization of novel N-glycan-based biomarkers in gastric cancer. PLoS One 8, e77821 (2013).
26. Blomme, B. et al. Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor. Mol Cell Biochem 372, 199-210 (2013).
27. Bartling, B. et al. Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma. Cancer Biomark 10, 145-54 (2011).
28. Ding, N. et al. Human serum N-glycan profiles are age and sex dependent. Age Ageing 40, 568-75 (2011).
29. Bayer, H. et al. Evaluation of riproximin binding properties reveals a novel mechanism for cellular targeting. J Biol Chem 287, 35873-86 (2012).
30. Nakagawa, T. et al. Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients. J Proteome Res 7, 2222-33 (2008).
31. Kamiyama, T. et al. Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology 57, 2314-25 (2013).
32. Dube, D. H. & Bertozzi, C. R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 4, 477-88 (2005).
33. Heimburg-Molinaro, J. et al. Cancer vaccines and carbohydrate epitopes. Vaccine 29, 8802-26 (2011).
34. Takamatsu, S. et al. Physiological and glycomic characterization of N-acetylglucosaminyltransferase-IVa and -IVb double deficient mice. Glycobiology 20, 485-97 (2010).
35. Yoshida, A. et al. Tissue specific expression and chromosomal mapping of a human UDP-N-acetylglucosamine: alpha1,3-dmannoside beta1, 4-N-acetylglucosaminyltransferase. Glycobiology 9, 303-10 (1999).
36. Taniguchi, N., Honke, K. & Fukuda, M. Handbook of glycosyltransferases and related genes. xviii, 670 p. (Springer, Tokyo, New York, 2002).
37. Taniguchi, N. & Korekane, H. Branched N-glycans and their implications for cell adhesion, signaling and clinical applications for cancer biomarkers and in therapeutics. BMB Reports 44, 772-781 (2011).
38. Schachter, H., Brockhausen, I. & Hull, E. High-Performance Liquid-Chromatography Assays for N-Acetylglucosaminyltransferases Involved In N-Glycan And O-Glycan Synthesis. Methods In Enzymology 179, 351-397 (1989).
39. Ohtsubo, K., Chen, M. Z., Olefsky, J. M. & Marth, J. D. Pathway to diabetes through attenuation of pancreatic beta cell glycosylation and glucose transport. Nature medicine 17, 1067-1075 (2011).
40. Niimi, K. et al. High expression of N-acetylglucosaminyltransferase IVa promotes invasion of choriocarcinoma. Br J Cancer 107, 1969-77 (2012).
41. Ide, Y. et al. Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer. Biochem Biophys Res Commun 341, 478-82 (2006).
42. D'Arrigo, A. et al. Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer 115, 256-62 (2005).
43. Deguchi, A., Hitoshi, S., Yoshimura, T., Fujimoto, I. & Ikeda, T. GnT V-Catalyzed N-glycan Products are not increased in Hepatomas. J Glycomics Lipidomics S5, 003 (2012).
44. Fan, J. et al. N-acetylglucosaminyltransferase IVa regulates metastatic potential of mouse hepatocarcinoma cells through glycosylation of CD147. Glycoconj J 29, 323-34 (2012).
45. Ohtsubo, K. et al. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell 123, 1307-21 (2005).
46. Helenius, A. & Aebi, M. Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem 73, 1019-49 (2004).
47. Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. TNM classification of malignant tumours. (John Wiley & Sons, 2011).
48. Yu, Y. et al. MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma. Cancer Sci 103, 716-22 (2012).
49. Shi, M., Yao, Y., Han, F., Li, Y. & Li, Y. MAP1S controls breast cancer cell TLR5 signaling pathway and promotes TLR5 signalingbased tumor suppression. PLoS One 9, e86839 (2014).